Humacyte’s Directors Exercise Zero‑Cost Options, Signaling Bullish Confidence in 2026‑2030 Growth Trajectory
Insider option buys at zero cost signal confidence in Humacyte’s future – investors may spot upside as execs bet on the bio‑tissue platform’s growth.
3 minutes to read